New Delhi, May 26 -- The Department of Pharmaceuticals has launched a new round of applications for drug manufacturers seeking to establish manufacturing facilities under the Production Linked Incentive (PLI) scheme.

The initiative targets 11 key pharmaceutical products that remain either unsubscribed or partially subscribed from previous phases of the program.

The designated products encompass critical antibiotics and analgesics, including Neomycin, Gentamycin, Erythromycin, Streptomycin, Tetracycline, Ciprofloxacin, and Diclofenac Sodium.

Interested manufacturers have until June 14 to submit their applications for consideration under this scheme designed to bolster India's domestic pharmaceutical production capabilities.

The PLI fra...